Journal of Hematology & Oncology (Aug 2024)
Continuous therapy in HHV-8 negative Multicentric Castleman Disease and prolonged progression-free survival
- Yi Liu,
- Xuejiao Yin,
- Shengnan Ding,
- Jiaying Ge,
- Liya Ma,
- Min Yang,
- Xuxia Luo,
- Chengli Zhong,
- Sishi Fang,
- Qiumei Yao,
- Li Zhu,
- Wenjuan Yu,
- Liping Mao,
- Juying Wei,
- Xingnong Ye,
- De Zhou,
- Hongyan Tong,
- Haitao Meng,
- Jie Jin,
- Liangshun You
Affiliations
- Yi Liu
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Xuejiao Yin
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Shengnan Ding
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Jiaying Ge
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Liya Ma
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Min Yang
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Xuxia Luo
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Chengli Zhong
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Sishi Fang
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Qiumei Yao
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Li Zhu
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Wenjuan Yu
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Liping Mao
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Juying Wei
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Xingnong Ye
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- De Zhou
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Hongyan Tong
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Haitao Meng
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Jie Jin
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- Liangshun You
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University
- DOI
- https://doi.org/10.1186/s13045-024-01588-9
- Journal volume & issue
-
Vol. 17,
no. 1
pp. 1 – 5
Abstract
Abstract The optimal treatment endpoints and duration of continuous therapy for multicentric Castleman disease (MCD) remain controversial. We retrospectively analyzed data from 123 patients with Human Herpesvirus (HHV)-8 negative MCD. We demonstrated that continuous therapy significantly enhanced progression-free survival (PFS) in patients who achieved an optimal response after initial treatment. These findings underscore the critical role of continuous therapy in HHV-8 negative MCD. Further studies with larger cohorts are required to validate these findings.
Keywords
